Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction
A Phase 1 Randomized, Double-blind, Placebo-controlled, Dose Escalation, Multicenter Study to Determine the Safety of Intravenous Ex-vivo Cultured Adult Human Mesenchymal Stem Cells (Provacel) Following Acute Myocardial Infarction
研究概览
详细说明
Cardiovascular disease is the single largest killer of males and females in the United States with an average of 335,000 deaths per year. This year an estimated 700,000 Americans will suffer an acute myocardial infarction. The standard of care treatment for acute myocardial infarction (MI) usually includes immediate perfusion, optimal pain relief, oxygen, aspirin or other anti-coagulants, Beta-Blockers, nitrates and Ace-inhibitors. Management of cardiac risk factors such as tobacco use, hypertension, lipid levels, diabetes, weight control and exercise all work to reduce further atherosclerotic events. Yet, many patients go on to develop Congestive Heart Failure (CHF). Medical management for CHF may improve symptoms and slow the progression to failure but does not restore a functioning myocardium. A therapy that could improve the myocardial remodeling process and reduce the incidence or severity of CHF following acute MI would provide a significant benefit in an area of unmet medical need.
Patients will receive standard of care in addition to stem cells or placebo.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85006
- Arizona Heart Institute
-
-
California
-
San Diego、California、美国、92103-8411
- University of California - San Diego; Thornton
-
-
District of Columbia
-
Washington、District of Columbia、美国、20010
- Washington Hospital Center
-
-
Illinois
-
Chicago、Illinois、美国、60612
- Rush University Medical Center
-
-
Indiana
-
Indianapolis、Indiana、美国、46260
- The Care Group
-
-
Kentucky
-
Louisville、Kentucky、美国、40202
- Jewish Hospital
-
-
Maryland
-
Baltimore、Maryland、美国、21205
- Johns Hopkins University
-
Takoma Park、Maryland、美国、20912
- Washington Adventist
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55407
- Minneapolis Heart Institute
-
-
New York
-
New York、New York、美国、10032
- Columbia Presbyterian Hospital
-
Rochester、New York、美国、14642
- University of Rochester - Strong Memorial
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- University of Pennsylvania Medical Center
-
-
Texas
-
Austin、Texas、美国、78756
- Austin Heart Institute
-
Houston、Texas、美国、77030
- Texas Medical School
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female between 21 and 85 years old
- First heart attack within 1 to 10 days
Exclusion Criteria:
- Positive for HIV 1 and 2
- Previous heart attack
- Pacemaker or other device
- Pregnant or breastfeeding
- Allergic to cow or pig derived products
- Previous bone marrow transplant
- Involved in another clinical trial within the past 30 days
- Alcohol or recreational drug abuse within the past 6 months
- Hepatitis Positive
- Major surgical procedure or major trauma within the past 14 days
- Body weight greater than 300 pounds
- Autoimmune disease ( e.g. Lupus, Multiple Sclerosis)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:Provacel: Cohort 1
ex vivo cultured adult mesenchymal stem cells
|
ex vivo cultured adult mesenchymal stem cells
|
有源比较器:Provacel: Cohort 2
ex vivo cultured adult mesenchymal stem cells
|
ex vivo cultured adult mesenchymal stem cells
|
有源比较器:Provacel: Cohort 3
ex vivo cultured adult mesenchymal stem cells
|
ex vivo cultured adult mesenchymal stem cells
|
有源比较器:Provacel: Cohort 4
ex vivo cultured adult mesenchymal stem cells
|
ex vivo cultured adult mesenchymal stem cells
|
安慰剂比较:Placebo
ex vivo cultured adult mesenchymal stem cells
|
安慰剂
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Comparison of treatment adverse event rates between the 0.5, 1.6 and 5.0 million mesenchymal stem cells per kilogram dose cohorts and placebo groups.
大体时间:6 months
|
6 months
|
合作者和调查者
调查人员
- 研究主任:Ken Borow, MD、Mesoblast, Inc.
出版物和有用的链接
一般刊物
- Orlic D, Hill JM, Arai AE. Stem cells for myocardial regeneration. Circ Res. 2002 Dec 13;91(12):1092-102. doi: 10.1161/01.res.0000046045.00846.b0.
- Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004 Jul 9;95(1):9-20. doi: 10.1161/01.RES.0000135902.99383.6f.
- Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, Pittenger MF, Martin BJ. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg. 2002 Jun;73(6):1919-25; discussion 1926. doi: 10.1016/s0003-4975(02)03517-8.
- Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009 Dec 8;54(24):2277-86. doi: 10.1016/j.jacc.2009.06.055.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
安慰剂的临床试验
-
City of Hope Medical CenterNational Cancer Institute (NCI)主动,不招人造血和淋巴细胞肿瘤 | 骨髓纤维化 | 慢性淋巴细胞白血病 | 缓解期成人急性髓性白血病 | 骨髓增生异常综合症 | 缓解期成人急性淋巴细胞白血病 | 骨髓增殖性肿瘤 | 慢性期慢性粒细胞白血病,BCR-ABL1 阳性 | 成人淋巴母细胞淋巴瘤 | 加速期慢性粒细胞白血病,BCR-ABL1 阳性 | HLA-A*0201 阳性细胞存在 | 巨细胞病毒感染 | 成人霍奇金淋巴瘤 | 成人非霍奇金淋巴瘤美国
-
Mila (bMotion Technologies)完全的
-
Universidad Autonoma de MadridCentro Universitario La Salle完全的